Ferguson opens OTC specialty shop

Share this article:

Feguson, a CommonHealth professional shop, launched a new “OTC Center of Excellence” focused on OTC marketing and promotion.

The group, led by EVP, director of client services Brian Doherty, will focus specifically on prescription drugs that transition to OTC, although the agency will also work on traditional OTC brands.

According to Doherty, who has been at CommonHealth for over a decade, the decision to launch an OTC group is a reflection of an evolving healthcare system. “Physicians aren't going to be able to devote as much time to ‘minor' conditions,” said Doherty, adding that self-care is on the rise. As a result, brand managers have to not only consider their share of the pharmacy shelf, but also their share of healthcare more generally, he said.

Doherty said Ferguson will bring its professional marketing experience to bear on OTC products. Although OTCs are governed by less strenuous marketing regulations than prescription drugs, “there are more similarities than differences,” said Doherty. “They still have to go through [internal] med/legal review.”

The OTC group will handle promotions for two of its preexisting clients—Novartis' line of consumer OTC products and Johnson & Johnson's oral and upper respiratory OTCs. Doherty said Ferguson worked on two of the most successful Rx-to-OTC transitions in history—presumably Zyrtec and Prevacid for J&J and Novartis, respectively—though Doherty refused to confirm specific brands.

The top nine out of 10 OTC brands switched from Rx to OTC, and one-third of OTC products overall contain an ingredient that was available by prescription-only at one time, said Doherty. “Work begins two or three years prior to patent expiration, and we continue to be in the brand creation business.” OTC products get a new label, and that's really where a brand begins, said Doherty.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Headliner: Ipsen head leads continental charge

Headliner: Ipsen head leads continental charge

"When I look at the business, I actually see patients in my mind. I don't see numbers."

Read the complete October 2014 Digital Edition

Read the complete October 2014 Digital Edition

Click the above link to access the complete Digital Edition of the October 2014 issue of MM&M, with all text, charts and pictures.

Predicting your pink slip

Predicting your pink slip

Any time a firm needs to save money, high-salaried executives are targets